Table 3: DAAs choices in special conditions [9,16,24,25].
Condition of the patients | Suggested regimens |
HBV/HCV coinfection | Risk of HBV reactivation during HCV treatment; Treatment for HBV is indicated for HBsAg (+) patients |
HIV/HCV coinfection | Same recommended regimen as patients without HIV; Drug-drug interactions should be carefully evaluated. |
CKD, stage 4 or 5 |
Elbasvir/grazoprevir (genotype 1,4), glecaprevir/pibrentasvir (genotype 1-6), or Ombitasvir/paritaprevir/r + dasabuvir (genotype 1,4) |
Decompensated Cirrhosis |
Genotype 1,4,5,6: Genotype 1,4: |